首页> 外文OA文献 >Overexpression of miRNA 4451 is Associated With a Poor Survival of Patients With Hypopharyngeal Cancer After Surgery With Postoperative Radiotherapy
【2h】

Overexpression of miRNA 4451 is Associated With a Poor Survival of Patients With Hypopharyngeal Cancer After Surgery With Postoperative Radiotherapy

机译:miRNA 4451的过表达与术后放射治疗后手术后的下咽癌患者的存活率差

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Hypopharyngeal cancer (HC) is the most common subset of head and neck cancers. These tumors often have an aggressive clinical outcome characterized by local invasion and regional nodal metastasis. Upregulated miRNAs might be useful as biomarkers for prognosis and molecular targets for these tumors. We determined tumor expression of candidate miRNAs using microarray in 8 HC patients and validated in 372 HC patients. We also used paired tumorous and mucosal tissue to verify the miRNA expression. Log-rank test and Cox model were used to evaluate the survival; and Harrell's C-index was used to compare concordance of Cox models. Our results indicated 7 miRNAs aberrantly expressed in HC. Three of these candidate miRNAs (miRNA-4415, miRNA-200a, and miRNA-30b) were selected for further qRT-PCR validation and all of them were frequently found upregulated in HC tumors; with miR-4451 being the most differentially expressed. Moreover, high expression of miR-4451 was positively correlated with advanced tumor stage and increased mortality risk (HR: 1.6, 95% CI: 1.2–2.3; adjusted HR: 1.5, adjusted 95% CI: 1.1–2.1). Finally, significantly higher expression of miR-4451 in tumors compared to in fresh adjacent normal tissues indicates an oncogenic role of miR-4451 in this tumor. Upregulated miR-4451 in HC samples were frequently found and is significantly associated with advanced stage and poor survival of HC, which may indicate an association of this miRNA with the carcinogenesis process in this tumor site; and they could serve as a prognostic biomarker as well as help develop potential new targets for therapy.
机译:下咽癌(HC)是最常见的头部和颈部癌症。这些肿瘤通常具有局部侵袭和区域节点转移的侵略性临床结果。上调的miRNA可能是可用作这些肿瘤预后和分子靶标的生物标志物。我们在8个HC患者中使用微阵列确定候选miRNA的肿瘤表达,并在372例HC患者中验证。我们还使用配对的肿瘤和粘膜组织来验证miRNA表达。日志秩测试和COX模型用于评估生存;和Harrell的C-Index用于比较COX模型的一致性。我们的结果表明,7名MiRNA在HC中表达。选择其中三种候选miRNA(miRNA-4415,miRNA-200a和miRNA-30b)进行进一步的QRT-PCR验证,并且在HC肿瘤中经常发现它们中的所有这些都会发现; miR-4451是最差异的表达。此外,MIR-4451的高表达与晚期肿瘤阶段呈正相关,增加死亡率风险(HR:1.6,95%CI:1.2-2.3;调整后的HR:1.5,调整95%CI:1.1-2.1)。最后,与新鲜相邻的正常组织相比,肿瘤中miR-4451的表达明显高出表明miR-4451在该肿瘤中的致癌作用。经常发现HC样品中的上调MiR-4451,并且与高级阶段和HC存活率显着相关,HC的存活率可能表明该miRNA与该肿瘤部位中的致癌过程的关联;他们可以作为预后的生物标志物,以及帮助制定潜在的治疗目标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号